# Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

> **NCT03522298** · PHASE2 · COMPLETED · sponsor: **Kazia Therapeutics Limited** · enrollment: 30 (actual)

## Conditions studied

- Glioblastoma, Adult

## Interventions

- **DRUG:** Paxalisib (GDC-0084)

## Key facts

- **NCT ID:** NCT03522298
- **Lead sponsor:** Kazia Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03522298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03522298, "Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03522298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*